Revenue rose 21.9% but losses widened 9.5% with cash down to $29.3m

Because top-line growth absorbed itself in operating losses rather than translating into reduced cash burn, the closing cash balance fell 11.9% to $29.3m and shareholders' equity eroded 34% to $54.6m as accumulated losses ate through the balance sheet. Capex was cut 53% to $1.4m (5.7% of revenue, down from 14.8%), and gross borrowings of $0.3m appeared on the balance sheet. Segment mix tilted further toward Commercial (84.4% of revenue versus 73.3%) while Research revenue fell from $7.3m to $4.4m.

With $29.3m of cash against a pre-lease free-cash outflow of $27.1m for the year (OCF −$25.8m plus capex of $1.4m), the current run-rate consumes most of the remaining cash within a 12-month window before any financing action. Equity fell by $28.1m, broadly tracking the reported loss, which means losses rather than capital returns drove the balance-sheet contraction, and the cash decline of only $4.0m implies non-cash liquid assets were drawn down to fund the shortfall. The capital position, not headline revenue growth, dictates strategic flexibility from here.

Growth is not yet creating operating leverage. Revenue +21.9% paired with a 9.5% wider PBT loss shows fixed-cost absorption is weak, and the cash conversion mechanic deteriorated versus the prior year. So the next dollar of revenue is still loss-making at the level visible in the segments.

Mix and volume composition matter. The 22% top-line gain was lifted by an 18% rise in US ASP per test, while US commercial test volumes grew only 2%. ASP-led growth is harder to repeat without coverage wins, which means the Medicare/coverage catalyst flagged by management is the real swing factor for FY25.

The supplied half-year shape shows 1H24 revenue of $13.1m versus implied 2H24 revenue of $10.8m, meaning revenue declined sequentially across the second half despite the full-year growth headline. Cash burn did improve second-half-on-first-half (1H24 OCF outflow of $15.0m, implied 2H24 outflow of $10.8m), which the announcement characterises as "Cash Burn Slows." That is the supportive signal in the result, but the offsetting concern is that revenue did not maintain the 1H run-rate. Whether that reflects seasonality, the deliberate sales-team reduction, or genuine top-line deceleration is not resolved in the release.

The 18% lift in ASP from US$519 to US$613 between 2H23 and 2H24 was attributed by the company to "improvements in cash collection," meaning some of the revenue uplift reflects collection of previously deferred amounts rather than steady-state pricing. Receivable days fell from 51.7 to 39.0 and trade debtors declined despite higher revenue, both consistent with that interpretation.

On the cost side, capex was cut 53%, the sales team was reduced and not backfilled, and capital intensity dropped to 5.7% of revenue. These choices reduced near-term cash outflow but indicate the company is now optimising for survival rather than reinvesting for growth. The durable read is therefore mixed: pricing improvement is real but partly catch-up, cost reductions are real but defensive, and operating leverage has not yet appeared in the segment results, where the Commercial segment loss widened slightly to $17.3m and the Research segment loss deepened to $12.3m.

This briefing cannot assess management's stated runway estimate, the probability of pending coverage decisions, or any post-balance-date capital raising not disclosed in the supplied materials.